ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study

Ding, Yangfeng; Li, Wei; Guan, Xin; Liu, Na; Zhou, Ying; Li, Gaojie; Wang, Xiaohua; Wang, Zhidong; Xiao, Xiao; Yang, Bin*; Lv, Chengzhi*; Zhang, Chunlei*; Shi, Yuling*北京大学; 南方医科大学; 四川大学; 同济大学
CTS-Clinical and Translational Science2023-10DOI: 10.1111/cts.13583
1被引11阅读
引用收藏
分享

摘要

Secukinumab is effective in treating patients with moderate-to-severe plaque psoriasis. However, most studies assessing its effectiveness in routine clinical settings in China are mostly single-center studies with a limited sample size. The objective of this study was to assess secukinumab's efficacy, treatment patterns, and characteristics in patients with moderate-to-severe plaque psoriasis. This 24-week, multicenter (n = 5) retrospective study analyzed the data of Chinese adult patients with moderate-to-severe plaque psoriasis who initiated secukinumab treatment between May 2019 and March 2020. The Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator's Global Assessment Modified 2011 (IGA mod 2011), and Dermatology Life Quality Index (DLQI) were assessed. Dermatologists documented the treatment dosage and modification reasons. Of the 244 secukinumab-naive patients, most were men (73.4%, 179/244) and weighed 60-90 kg (72.8%, 177/243). The mean (SD) age at secukinumab initiation was 38.1 (11.6) years, and the disease duration was 13.5 (7.9) years. Most patients (97.1%, 237/244) received secukinumab 300 mg. At weeks 4, 12, 16, and 24, the proportion of patients achieving PASI 75 = 75% reduction from baseline) was 40.0%, 92.1%, 88.4%, and 88.9%, respectively; PASI 90 was 15.0%, 73.7%, 81.4%, and 68.3%, respectively; and PASI 100 was 8.7%, 40.8%, 58.1%, and 41.3%, respectively. During the same periods, BSA and IGA mod 2011 showed similar improvement trends. An increasing proportion of patients achieved DLQI of 0-1 (21.6%, 65.7%, 75.0%, and 80.3%, respectively). Treatment modification was highest at week 12. The average interval between two administrations after week 4 was 62.95 days. Secukinumab was highly effective in improving the PASI, IGA, BSA, and DLQI in Chinese patients with moderate-to-severe plaque psoriasis throughout the first 24 weeks. The treatment pattern for Chinese patients differs from that in the clinical guidelines.

学科与关键词

关键词
QUALITY-OF-LIFESAFETYINDEXEFFICACYAREAVULGARISDECISION
相关
加载中…
  • Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Chinese Medical Journal, 2020, 133(22): 2665-2673.
  • A retrospective study to assess the efficacy, safety, and drug survival of secukinumab in plaque psoriasis patients in China
    Wang, Yu; Wang, Xiaohua; Yu, Yixin; Yuan, Liyan; Yu, Xiaoling; Yang, Bin*Dermatologic Therapy, 2021, 34(5): e15081.被引 4
  • Interim analysis of a real-world retrospective multicenter study: Evaluation of effectiveness of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China
    Liu, N.; Xiao, X.; Pan, R.; Li, W.; Yang, B.; Shi, Y.
查看全部 →

发表信息

论文状态
公开发表
期刊
CTS-Clinical and Translational Science
发表日期
2023-10
卷期
第 16 卷, 第 10 期
页码
1803-1814
DOI
10.1111/cts.13583
语言
ENGLISH
成果收录
SCIE
资助标注
All authors contributed to the conception and design of the study, medical writing, and interpretation of the results. All clinician investigators collected data with the support of Novartis. The authors would like to thank Dr Zheng Yin, Dr Hsu-Wen Chou, a; Beijing Novartis Pharma Co. Ltd.

作者

  • D

    Ding, Yangfeng (第一作者)

    tongji univ

  • L

    Li, Wei

    sichuan univ

查看全部 13 位作者收起作者
  • G

    Guan, Xin

    peking univ

  • L

    Liu, Na

  • Z

    Zhou, Ying

  • L

    Li, Gaojie

    sichuan univ

  • W

    Wang, Xiaohua

    southern med univ

  • W

    Wang, Zhidong

  • X

    Xiao, Xiao

  • Y

    Yang, Bin (通讯)

    2 · southern med univ

  • L

    Lv, Chengzhi (通讯)

  • Z

    Zhang, Chunlei (通讯)

    peking univ

  • S

    Shi, Yuling (通讯)

    tongji univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417